Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 19/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22975479 | 0.93 | NT5E (0.77) | NT5E | |
| SCHEMBL23007445 | 0.92 | NT5E (0.65) | NT5E | |
| SCHEMBL23007473 | 0.91 | NT5E (0.68) | NT5E | |
| SCHEMBL27199103 | 0.91 | NT5E (0.78) | NT5EADORA3 | |
| SCHEMBL22975552 | 0.91 | NT5E (0.78) | NT5EADORA3 | |
| SCHEMBL26720724 | 0.90 | NT5E (0.70) | NT5E | |
| SCHEMBL23007026 | 0.90 | NT5E (0.77) | NT5E | |
| SCHEMBL23007471 | 0.89 | NT5E (0.64) | NT5EADORA3ADORA2AADORA1 | |
| SCHEMBL23007472 | 0.89 | NT5E (0.63) | NT5E | |
| SCHEMBL23007474 | 0.89 | NT5E (0.65) | NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807658-B2 | CD73 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807658-B2 | CD73 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20220220147-A1 | CD73 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2022-07-14 | — | — | US | disclosed |
| US-11325938-B2 | CD73 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-20210047359-A1 | CD73 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807658-B2 | CD73 inhibitors | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885ADORA3 19/4885ADORA2A 11/4885 |
| US-20220220147-A1 | CD73 INHIBITORS | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885ADORA3 19/4885ADORA2A 11/4885 |
| US-11325938-B2 | CD73 inhibitors | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885ADORA3 19/4885ADORA2A 11/4885 |
| US-20210047359-A1 | CD73 INHIBITORS | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885ADORA3 19/4885ADORA2A 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.